Summary for Fish Oil Triglycerides


Pediatric
  • Trade Name: Omegaven (Fresenius Kabi USA)
  • Indications: indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis
  • FDA Approval Date: 07/27/2018
  • Clinically important, potentially hazardous interactions with:
    None known
  • Pregnancy: no available data

Risk of Death in Preterm Infants due to Pulmonary Lipid Accumulation; Hypersensitivity Reactions; Risk of Infections, Fat Overload Syndrome, Refeeding Syndrome, and Hypertriglyceridemia; Aluminum Toxicity

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top